Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Completed · Phase 3

Conditions studied: Atypical Hemolytic Uremic Syndrome

In brief

The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.

Key facts

Study ID

NCT04889430

Run by

Novartis Pharmaceuticals

People needed

34

Starts

2022-01-17

Expected to finish

2026-04-11

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC Norris Cancer Center — Los Angeles, California, United States
• Univ of California at Los Angeles — Los Angeles, California, United States
• Univ Cali Irvine ALS Neuromuscular — Orange, California, United States
• Univ of California at Sacramento — Sacramento, California, United States
• Harbor-UCLA Medical Center . — Torrance, California, United States
• Georgetown University Lombardi Cancer Center — Washington D.C., District of Columbia, United States
• University Of Miami — Miami, Florida, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Montefiore Medical Center . — The Bronx, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• University of Cincinnati — Cincinnati, Ohio, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Comprehensive Transplant Ctr at OSU — Columbus, Ohio, United States
• UT Southwestern Medical Center — Dallas, Texas, United States
• Virginia Commonwealth University — Richmond, Virginia, United States
• Novartis Investigative Site — Fortaleza, Ceará, Brazil
• Novartis Investigative Site — Brasília, Federal District, Brazil
• Novartis Investigative Site — Belo Horizonte, Minas Gerais, Brazil
• Novartis Investigative Site — Recife, Pernambuco, Brazil
• Novartis Investigative Site — Porto Alegre, Rio Grande do Sul, Brazil
• Novartis Investigative Site — São Paulo, São Paulo, Brazil
• Novartis Investigative Site — São Paulo, São Paulo, Brazil
• Novartis Investigative Site — São Paulo, São Paulo, Brazil
• Novartis Investigative Site — Rio de Janeiro, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.